6/24/2019  9:59:14 PM Chg. -0.10 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
7.40USD -1.27% 11,984
Turnover: 90,270.37
-Bid Size: - -Ask Size: - 360.49 mill.USD 0.00% -

Business description

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, post-stroke walking difficulties, migraine, and multiple sclerosis.
 

Management board & Supervisory board

CEO
Ron Cohen
Management board
Andrew A. Hindman, Burkhard Blank, David Lawrence, Denise Duca, Dr. Andrew R. Blight, Jane Wasman, Lauren Sabella, Tierney Saccavino
Supervisory board
Barry Greene, Dr. Catherine D. Strader, Dr. Sandra Panem, John P. Kelley, Lorin J. Randall, Peder K. Jensen, Ron Cohen, Steven M. Rauscher
 

Company data

Name: Acorda Therapeutics Inc.
Address: 420 Saw Mill River Road,Ardsley, New York 10502, USA
Phone: +1-914-347-4300
Fax: +1-914-347-4560
E-mail: info@acorda.com
Internet: www.acorda.com/
Industry: Healthcare
Sector: Healthcare Providers
Sub sector: Healthcare Providers
End of financial year: 12/31
Free Float: 31.30%
IPO date: -

Investor relations

Name: Felicia Vonella
IR phone: +1-914-326-5146
IR-Fax: -
IR e-mail: fvonella@acorda.com

Main Shareholders

Freefloat
 
31.30%
FMR LLC
 
14.80%
BlackRock, Inc.
 
13.90%
The Vanguard Group
 
12.70%
Scopia Capital Management
 
9.70%
Partner Fund Management
 
6.00%
Dimensional Fund Advisors LP
 
6.00%
State Street
 
5.60%